{"entity":{"id":"nct04543279","kind":"trial","name":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia","aka":[],"tldr":"A phase 2 trial of Fostamatinib and Ruxolitinib in Primary myelofibrosis, run by Washington University School of Medicine, recorded as terminated on the registry.","summary":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia is a phase 2 interventional study registered as NCT04543279 by Washington University School of Medicine, with 3 participants recorded, started 2021-05-03 and due to reach its primary completion in 2022-07-01. Interventions recorded: Fostamatinib, Ruxolitinib. Conditions recorded: Myelofibrosis, Thrombocytopenia.\n\nLinked to the drug Fostamatinib because the registry names it among its interventions and Primary myelofibrosis among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04543279","url":"https://clinicaltrials.gov/study/NCT04543279"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["primary-myelofibrosis"],"sections":[],"technologies":[],"targets":[],"drugs":["fostamatinib","ruxolitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04543279","phase":"2","setting":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia","sponsor":"Washington University School of Medicine","started":"2021-05-03","startedType":"actual","yearReported":2023,"enrolled":3,"enrolledBasis":"registry","outcomes":[{"endpoint":"Number of Participants With a Platelet Response (Part A)","primary":true,"unit":"participants","arms":[{"name":"Part A: Fostamatinib","n":3,"value":0,"note":"Figures from the ClinicalTrials.gov results section (first posted 2023-12-15), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04543279?tab=results"}]},"route":"/trials/nct04543279/","neighbours":{"cancer":[{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/"}],"drug":[{"id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/"},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"}]}}